Descdescribe andi of breast in detail

Reading File

Finding Sources

Reading File

I now have comprehensive content from multiple textbooks. Let me compile the detailed answer.

ANDI - Aberrations of Normal Development and Involution of the Breast

1. Background and Nomenclature

The term ANDI (Aberrations of Normal Development and Involution) was developed and described by the Cardiff Breast Clinic (UK) and published by Hughes, Mansel, and Webster in The Lancet (1987). It replaced a confusing array of older terms - fibroadenosis, chronic mastitis, fibrocystic disease, cystic hyperplasia, benign mammary dysplasia, mastopathy - none of which adequately explained the pathogenesis or related well to clinical or histological features.

The ANDI concept recognizes that most benign breast disorders are not true diseases but minor aberrations of the normal physiological processes of breast development, cyclical hormonal change, and involution. It provides a spectrum from normality through disorder to frank disease.

Bailey and Love's Short Practice of Surgery, 28th Ed., p. 940
Schwartz's Principles of Surgery, 11th Ed., p. 579

2. The ANDI Framework: A Spectrum from Normal to Disease

ANDI is organized around three phases of breast life, each with a Normal - Disorder - Disease spectrum:

Phase	Age	Normal	Disorder	Disease
Early Reproductive	15-25 years	Lobular development; Stromal development; Nipple eversion	Fibroadenoma; Adolescent hypertrophy; Nipple inversion	Giant fibroadenoma; Gigantomastia; Subareolar abscess; Mammary duct fistula
Later Reproductive	25-40 years	Cyclical changes of menstruation; Epithelial hyperplasia of pregnancy	Cyclical mastalgia; Nodularity; Bloody nipple discharge	Incapacitating mastalgia
Involution	35-55 years	Lobular involution; Duct involution (dilatation, sclerosis); Epithelial turnover	Macrocysts; Sclerosing lesions; Duct ectasia; Nipple retraction; Epithelial hyperplasia	Periductal mastitis; Epithelial hyperplasia with atypia

Schwartz's Principles of Surgery, 11th Ed., Table 17-2

3. Aetiology

The breast is a dynamic structure undergoing continuous change due to cyclical fluctuations in oestrogen and progesterone during every menstrual cycle. These hormones act as growth factors on the epithelial and stromal cells of the terminal ducto-lobular unit (TDLU).

The aetiology of ANDI is not fully understood, but involves:

Cyclical changes in hormonal environment
Effects of oral contraceptive pills
Hormone replacement therapy
Dietary factors
Smoking

The aberrations result from very minor hormonal imbalances accumulated over multiple menstrual cycles.

4. Pathology

Considered in three phases corresponding to the ANDI classification:

Phase 1 - Lobule Development (15-25 years)

Lobular proliferation leads to fibroadenoma formation
Excessive stromal development causes adolescent hypertrophy or gigantomastia
Disorder of major duct development results in nipple inversion, predisposing to duct obstruction, subareolar abscess, and mammary duct fistula

Phase 2 - Cyclical Changes (15-50 years)

Normal premenstrual breast enlargement; when exaggerated becomes cyclical mastalgia
Epithelial hyperplasia of pregnancy - papillary projections can cause bilateral bloody nipple discharge

Phase 3 - Involution (35-55 years)

Involution of lobular epithelium is dependent on the specialized stroma around it. When stroma and epithelium do not involute in an integrated fashion:

Stroma involutes too quickly → alveoli remain → form microcysts → coalesce into macrocysts
Sclerosing adenosis - disorder of both proliferative and involutional phases
Duct ectasia - ductal dilatation with periductal inflammation
Periductal mastitis - periductal fibrosis is its sequela, causing nipple retraction
~60% of women ≥70 years show some epithelial hyperplasia

Microscopic changes in ANDI include:

Adenosis
Cyst formation
Papillomatosis
Epithelial hyperplasia (with or without atypia)
Fibrosis
Lymphocytic infiltration

Hyperplasia grading:

2 cell layers in duct/acini lining = hyperplasia
With atypia: Atypical Ductal Hyperplasia (ADH) or Atypical Lobular Hyperplasia (ALH)
ADH involving >2 ducts or >2 mm in diameter = Ductal Carcinoma In Situ (DCIS)

5. Clinical Features

The most common manifestations are:

A. Mastalgia (Breast Pain)

Affects 50-70% of women attending breast clinics. Two types:

Cyclical Mastalgia:

Starts around day 14 of the menstrual cycle
Gradually increases in severity until day 27-28
Usually bilateral; relieved with onset of menses
Severe forms cause loss of sleep, impaired daily activities, sexual difficulties
Strongly associated with ANDI

Non-cyclical Mastalgia:

Irregular or continuous pain
Usually NOT associated with ANDI
May relate to musculoskeletal chest wall pain, duct ectasia, or periductal mastitis
Persistent localized pain must raise suspicion of carcinoma

B. Nodularity / Breast Lumps

Nodularity is often bilateral and most conspicuous in the upper outer quadrant
May be cyclical (appears 1-2 weeks before menstruation; regresses with menses)
Discrete lumps:
- Fibroadenoma - commonest in young women (15-30 years)
- Cysts - commonest in middle-aged women (35-55 years)
Lumps fluctuate in size with menstrual cycle (characteristic of ANDI; helps exclude carcinoma)
Benign lumps and cysts are mobile, not fixed, not tethered to skin or deep structures; axillary nodes not enlarged

Cyst characteristics:

Smooth, round, variable consistency (very tense cysts may not fluctuate)
"Blue-domed cyst of Bloodgood" - solitary macrocyst
Aspirate: non-blood-stained; cyst disappears completely; does not refill

C. Nipple Discharge

Greenish or serous discharge from the nipple is common
Bloody bilateral nipple discharge may occur with epithelial hyperplasia in pregnancy

6. Key Disorders in Detail

Fibroadenoma

Aberration of lobule development
Two histological types:
- Pericanalicular - fibrous tissue surrounding tubular glands; hard, smaller; age 15-30 years
- Intracanalicular - glands stretched into elongated shapes by fibrous tissue; softer, larger; age 35-50 years
"Breast mouse" or "floating tumour" - highly mobile, no tethering
Risk: giant fibroadenoma (disease end) and rare transformation to cystosarcoma phyllodes

Cyclical Mastalgia

Pain score measured on a Visual Analogue Scale (VAS 0-10)
Considered a disorder when pain persists >1 week of the cycle and score >3/10

Macrocysts

Precursor: microcysts (from premature stroma involution)
Common, often subclinical, do not require specific treatment unless symptomatic
Aspiration is both diagnostic and therapeutic

Sclerosing Adenosis

Disorder of both proliferative and involutional phases
Histologically mimics carcinoma; biopsy required to exclude malignancy

Duct Ectasia / Periductal Mastitis

Duct ectasia = dilatation of subareolar ducts with inspissated secretions
Periductal mastitis follows; periductal fibrosis causes nipple retraction
Associated with smoking

Epithelial Hyperplasia (Involution phase)

ADH carries relative risk for cancer of ~4
ALH carries relative risk of ~4-5 (higher with family history)

7. Investigation

Triple Assessment is mandatory for any discrete lump or focal nodularity:

Clinical examination
Imaging - Ultrasound (young <35 years); Mammography (>35 years)
Fine Needle Aspiration Cytology (FNAC) / Core biopsy

For cysts: aspiration confirms diagnosis (non-bloody fluid, complete disappearance, no recurrence, negative cytology = benign)

8. Management

Mastalgia Management (stepwise):

Step	Treatment	Notes
1	Exclude cancer; reassure	Most cases respond to reassurance
2	Adequate support	Tight sports bra day and night
3	Evening primrose oil / Flaxseed 30g/day	Rich in gamma-linolenic acid / omega-3
4	Topical NSAIDs	Diclofenac or piroxicam 4x/day (mild-moderate pain)
5	Tamoxifen 10 mg/day	3-6 months (VAS >3); most effective
6	Danazol 50-300 mg/day	3-6 months; androgenic side effects
7	Ormeloxifene 30 mg twice/week	3-6 months; both cyclical and non-cyclical
8	LHRH agonist ± anti-oestrogen	3 months; recalcitrant cases only

Nodularity:

With mastalgia: treat the pain (above)
Without pain: triple assessment; reassurance if no discrete lesion; tamoxifen or ormeloxifene if needed

Fibroadenoma:

Small (<3 cm), young patient: watchful waiting is acceptable (majority involute with time)
Large, enlarging, or >35 years: surgical excision

Cysts:

Aspiration - diagnostic and therapeutic
Re-examine in several weeks; if re-accumulates or residual mass, excise

9. Cancer Risk in ANDI

Lesion	Relative Risk for Breast Cancer
Non-proliferative (no hyperplasia)	No increased risk
Hyperplasia without atypia	1.5-2x
Solitary papilloma	1.5-2x
Papillomatosis (5+ papillomas)	~3x
ADH or ALH	~4-5x
ADH/ALH + positive family history	8-10x

Summary

ANDI is the accepted framework for understanding benign breast disorders. The key concept is that these conditions represent points on a continuum from normal physiology to disorder to frank disease, driven by hormonal influences on the TDLU across a woman's reproductive life. Management is guided by the specific disorder, its position on the ANDI spectrum, and the need to exclude malignancy through triple assessment.

Bailey and Love's Short Practice of Surgery, 28th Ed.
Schwartz's Principles of Surgery, 11th Ed.
S. Das: A Manual on Clinical Surgery, 13th Ed.

This is a shared conversation. Sign in to Orris to start your own chat.